The Cognivue Product Line
Cognivue has expanded its product offerings and now offers a portable device.
Utilizing Cognivue’s FDA-cleared technology and proprietary algorithm, this 10-minute self-administered computerized assessment is simple to implement in a Physician’s medical environment and easily fits in to the workflow of a busy practice.Learn More
Cognivue Thrive utilizes the same FDA-cleared technology that’s been used by neurologists and other physicians to test for cognitive function. This 5-minute self-administered computerized screening is simple to implement in any clinical environment and requires minimal staff involvement.Learn More
Cognivue objectively, quantitatively and reliably identifies changes in cognitive function that could be indicative of an impairment that you may optimally treat or manage.
Assesses all cognitive domains with a highly sensitive test that is supported by the science of adaptive psychophysics.
Calibrated the same across all devices, ensuring consistency and retest reliability while eliminating human error in administering and scoring the test.
Patient administered, producing a report that's easy to understand and communicate, with clinically meaningful correlations within key cognitive domains.
Cognivue’s FDA Clearance Data Published in the World Journal of Psychiatry
Cognivue is an important and innovative psychometric tool for cognitive evaluation. This article describes data that are fundamental indicators of its sophistication in evaluating cognitive impairment and cost-effective applicability in clinical practice.Learn More
Empowering you to Take Control of Your Cognitive Health.
Evidence based recommendations on how to proactively manage lifestyle-related risk factors and certain medical conditions that affect cognition.Learn More
Thank you Cognivue for the easiest and most credible cognitive health screener I’ve ever used.Albert F. Turri, Au.D.
Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)
ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…
Sign-up to schedule a Cognivue demo!Click Here